TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32600261

Group type: EXPERIMENTAL
Intervention: tcensReg method for estimating population mean and variance from censored observations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tobit regression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single imputation
Number of subjects: 0
Study: 32600369

Group type: EXPERIMENTAL
Intervention: TAVR with Sapien 3
Number of subjects: 2000

Group type: COMPARATOR
Intervention: SAVR with Perimount Magna Ease
Number of subjects: 2000
Study: 32600373

Group type: EXPERIMENTAL
Intervention: Silicone-coated PVC ETTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noble-metal-coated PVC ETTs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncoated PVC ETTs
Number of subjects: 0
Study: 32600374

Group type: EXPERIMENTAL
Intervention: Renal imaging biomarkers (magnetic resonance imaging (MRI) and ultrasound (US))
Number of subjects: 500
Study: 32600857

Group type: EXPERIMENTAL
Intervention: Multimodal intervention including fish oil intake (2g daily), dietary counselling, and unsupervised physical exercise twice weekly during the first three cycles of treatment
Number of subjects: 123

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 123
Study: 32601111

Group type: EXPERIMENTAL
Intervention: EA (Expériences Animées) programme using animated short movies and discussions about psychoactive substances and addictions.
Number of subjects: 10
Study: 32601114

Group type: EXPERIMENTAL
Intervention: Burosumab treatment
Number of subjects: 160
Study: 32601169

Group type: EXPERIMENTAL
Intervention: Caspofungin standard dosing
Number of subjects: 0
Study: 32601337

Group type: EXPERIMENTAL
Intervention: Cusatuzumab
Number of subjects: 0
Study: 32601378

Group type: EXPERIMENTAL
Intervention: Venetoclax-based combinations
Number of subjects: 0
Study: 32601850

Group type: EXPERIMENTAL
Intervention: WATCHMAN LAAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laboratory thrombosis and hemostasis markers
Number of subjects: 0
Study: 32602006

Group type: EXPERIMENTAL
Intervention: Kidney dysfunction upon admission (eGFR < 60 mL/min/1.73 m²)
Number of subjects: 758

Group type: COMPARATOR
Intervention: eGFR > 60 mL/min/1.73 m²
Number of subjects: 758
Study: 32602562

Group type: EXPERIMENTAL
Intervention: Online survey assessment of physical and mental well-being
Number of subjects: 253
Study: 32602677

Group type: EXPERIMENTAL
Intervention: High-risk zone posting
Number of subjects: 3667

Group type: COMPARATOR
Intervention: Low-risk zone posting
Number of subjects: 3667

Group type: EXPERIMENTAL
Intervention: Symptomatic HCWs
Number of subjects: 3667

Group type: COMPARATOR
Intervention: Asymptomatic HCWs
Number of subjects: 3667

Group type: EXPERIMENTAL
Intervention: HCQ prophylaxis
Number of subjects: 3667
Study: 32603248

Group type: EXPERIMENTAL
Intervention: Venovenous extracorporeal membrane oxygenation (VV-ECMO)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 64
Study: 32603426

Group type: EXPERIMENTAL
Intervention: Sirolimus with cyclosporine (CSP) and mycophenolate mofetil (MMF)
Number of subjects: 77
Study: 32603847

Group type: EXPERIMENTAL
Intervention: Percutaneous-only access techniques
Number of subjects: 4781

Group type: COMPARATOR
Intervention: Cutdown-only access techniques
Number of subjects: 4781

Group type: COMPARATOR
Intervention: Combined access techniques
Number of subjects: 4781

Group type: COMPARATOR
Intervention: TEVAR group
Number of subjects: 4781

Group type: COMPARATOR
Intervention: EVAR group
Number of subjects: 4781

Group type: EXPERIMENTAL
Intervention: Overall LOS
Number of subjects: 4781
Study: 32604132

Group type: EXPERIMENTAL
Intervention: HIV-exposed, uninfected infants (HEU)
Number of subjects: 238

Group type: COMPARATOR
Intervention: HIV-unexposed, uninfected infants
Number of subjects: 238
Study: 32604962

Group type: EXPERIMENTAL
Intervention: Abatacept + MTX with GC (≤10 mg/day)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Abatacept + MTX without GC (no-GC)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Adalimumab + MTX with GC (≤10 mg/day)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Adalimumab + MTX without GC (no-GC)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Both treatments (abatacept and adalimumab)
Number of subjects: 646
Study: 32605050

Group type: EXPERIMENTAL
Intervention: Hypo-fractionated stereotactic radiation (HFSRT; 6 Gy × 5) plus pembrolizumab (100 or 200 mg, every 3 weeks) and bevacizumab (10 mg/kg, every 2 weeks)
Number of subjects: 14
Study: 32605298

Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 374

Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 374
Study: 32605575

Group type: EXPERIMENTAL
Intervention: sTREM-1
Number of subjects: 4989

Group type: EXPERIMENTAL
Intervention: sTREM-1 combined with clinical variables
Number of subjects: 4989

Group type: COMPARATOR
Intervention: Clinical variables alone
Number of subjects: 4989
Study: 32605623

Group type: EXPERIMENTAL
Intervention: 3 Wishes Project (3WP) implementation
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Local adaptations of 3WP
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Semi-structured nature of the program
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Team approach to care
Number of subjects: 85
Study: 32605637

Group type: EXPERIMENTAL
Intervention: CTRCD group
Number of subjects: 43

Group type: COMPARATOR
Intervention: non-CTRCD group
Number of subjects: 43
Study: 32605888

Group type: EXPERIMENTAL
Intervention: Pembrolizumab before radical cystectomy
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Combination of all MRI sequences
Number of subjects: 143
Study: 32606056

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potential risk factors
Number of subjects: 0
Study: 32606066

Group type: EXPERIMENTAL
Intervention: Consensus-based recommendations for perioperative medication safety tailored to country income level
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Online surveys using RedCAP
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Semistructured interviews
Number of subjects: 108
Study: 32606101

Group type: EXPERIMENTAL
Intervention: Embolus Retriever with Interlinked Cages (ERIC)
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Standard Stent Retrievers (SRs)
Number of subjects: 1230
Study: 32606573

Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05% (PRO-145)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Prednisolone acetate 1%
Number of subjects: 178
Study: 32606580

Group type: EXPERIMENTAL
Intervention: VisuEvo (VSE)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (CTN)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 72
Study: 32606578

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 or 0.5 mg
Number of subjects: 759

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 759
Study: 32606705

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate three monthly (PP3M)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once monthly (PP1M)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Oral paliperidone extended release (paliperidone ER)
Number of subjects: 922

Group type: COMPARATOR
Intervention: Placebo (non-adherent patients)
Number of subjects: 922
Study: 32606883

Group type: EXPERIMENTAL
Intervention: Vedolizumab (induction and maintenance)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo (induction and maintenance)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Vedolizumab/Placebo (vedolizumab induction, placebo maintenance)
Number of subjects: 454
Study: 32606899

Group type: EXPERIMENTAL
Intervention: Active treatment (LICUS, 3MHz, 0.132W/cm, 18,720 Joules)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Active treatment (LICUS)
Number of subjects: 33
Study: 32606903

Group type: EXPERIMENTAL
Intervention: 1 mg nalbuphine with 12.5 mg hyperbaric bupivacaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2.5 mg midazolam with 12.5 mg hyperbaric bupivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: 12.5 mg hyperbaric bupivacaine plus 0.5 mL saline (Control)
Number of subjects: 90
Study: 32606902

Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8% under heat conditions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8% under exercise conditions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lidocaine topical system 1.8% under normal conditions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8% under all conditions
Number of subjects: 12
Study: 32606914

Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8%
Number of subjects: 110

Group type: COMPARATOR
Intervention: Lidocaine patch 5%
Number of subjects: 110
Study: 32606956

Group type: EXPERIMENTAL
Intervention: Icotinib (125 mg 3 times per day)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo (125 mg 3 times per day)
Number of subjects: 124
Study: 32607095

Group type: EXPERIMENTAL
Intervention: Plant-derived natural products
Number of subjects: 0
Study: 32607502

Group type: EXPERIMENTAL
Intervention: Peer-delivered behavioral intervention for ART adherence and substance use
Number of subjects: 60

Group type: COMPARATOR
Intervention: Enhanced standard of care (facilitating referral to a local substance use treatment clinic)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Peer-delivered intervention
Number of subjects: 60
Study: 32607720

Group type: EXPERIMENTAL
Intervention: Families who authorized organ donation
Number of subjects: 1651

Group type: COMPARATOR
Intervention: Families who refused organ donation
Number of subjects: 1651
Study: 32607929

Group type: EXPERIMENTAL
Intervention: Simple Segmentation Tool (SST) administered by physicians and nurses
Number of subjects: 0
Study: 32607967

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vancomycin plus Aztreonam
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 42
Study: 32608505

Group type: EXPERIMENTAL
Intervention: Psychological therapies (various types including integrative, humanistic, cognitive behavioural, and third-wave cognitive behavioural therapies)
Number of subjects: 5517

Group type: EXPERIMENTAL
Intervention: Psychological therapies (various types)
Number of subjects: 5517
Study: 32608579

Group type: EXPERIMENTAL
Intervention: Anti-CD19 and anti-CD20 CAR-T cells
Number of subjects: 21
Study: 32609374

Group type: COMPARATOR
Intervention: External uterine compression
Number of subjects: 944

Group type: COMPARATOR
Intervention: Uterine arterial embolisation
Number of subjects: 944

Group type: COMPARATOR
Intervention: Balloon tamponade (condom catheter)
Number of subjects: 944

Group type: COMPARATOR
Intervention: Balloon tamponade (latex balloon catheter)
Number of subjects: 944

Group type: COMPARATOR
Intervention: Bakri balloon tamponade
Number of subjects: 944

Group type: COMPARATOR
Intervention: Comparison of intrauterine tamponade methods (Bakri balloon vs condom catheter)
Number of subjects: 944

Group type: COMPARATOR
Intervention: Comparison of intrauterine tamponade methods (Bakri balloon vs gauze packing)
Number of subjects: 944

Group type: COMPARATOR
Intervention: Modified B-Lynch compression suture
Number of subjects: 944
Study: 32609959

Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Number of subjects: 0
Study: 32610059

Group type: EXPERIMENTAL
Intervention: SMS-PCP (primary care physician endorsed SMS)
Number of subjects: 14438

Group type: EXPERIMENTAL
Intervention: SMS-PCP
Number of subjects: 14438

Group type: EXPERIMENTAL
Intervention: SMS (no manipulation)
Number of subjects: 14438

Group type: COMPARATOR
Intervention: Control (no SMS)
Number of subjects: 14438
Study: 32610581

Group type: EXPERIMENTAL
Intervention: Pimasertib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 0
Study: 32611221

Group type: EXPERIMENTAL
Intervention: Spring
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Summer
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Autumn
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Winter
Number of subjects: 1113
Study: 32611374

Group type: EXPERIMENTAL
Intervention: miR-200 family (miR-200a, miR-200b, miR-200c) isolated from tumor tissue and plasma
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: miR-200 family isolated from urine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Correlation of miRNA-200 expression in urine and plasma
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Plasma and urine for miRNA detection
Number of subjects: 16
Study: 32611397

Group type: EXPERIMENTAL
Intervention: Interventional pain management
Number of subjects: 19
Study: 32611546

Group type: EXPERIMENTAL
Intervention: RTI risk assessment screening tool
Number of subjects: 303
Study: 32611608

Group type: EXPERIMENTAL
Intervention: Fasting serum fructose levels
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Fasting serum fructose levels (after adjustment for additional factors)
Number of subjects: 949
Study: 32611642

Group type: EXPERIMENTAL
Intervention: MRI with short TI inversion recovery to identify regions of interest (ROIs) with hyperintensities indicating muscle inflammation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Muscle T2 relaxation time mapping as a quantitative marker of muscle inflammation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dixon sequences to quantify muscle fat replacement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy controls examined with a magnetic resonance scan once for determination of normal values of T2 relaxation time
Number of subjects: 10
Study: 32611662

Group type: EXPERIMENTAL
Intervention: Adverse drug reactions in patients with CKD
Number of subjects: 3033

Group type: EXPERIMENTAL
Intervention: Specific pharmacologic classes (antithrombotic agents)
Number of subjects: 3033
Study: 32611728

Group type: EXPERIMENTAL
Intervention: Lower dose of alteplase
Number of subjects: 3479

Group type: COMPARATOR
Intervention: Standard dose of alteplase
Number of subjects: 3479
Study: 32611729

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI (DCE-MRI) before and 6 months after endovascular treatment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Quantitative analysis of the vasa vasorum in the IMH
Number of subjects: 80
Study: 32611739

Group type: EXPERIMENTAL
Intervention: Therapy-naïve patients receiving standard PIBD care with follow-up up to 20 years.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extensive immunological analyses including blood samples and intestinal biopsies.
Number of subjects: 0
Study: 32611743

Group type: EXPERIMENTAL
Intervention: RaceRunning intervention (one session each week for 24 weeks)
Number of subjects: 25
Study: 32611742

Group type: EXPERIMENTAL
Intervention: Longitudinal questionnaire survey
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Data from population-based registries
Number of subjects: 902
Study: 32611745

Group type: EXPERIMENTAL
Intervention: Development of a patient-reported outcome (PRO) tool for measuring flare in IBD based on messages from an internet forum.
Number of subjects: 0
Study: 32612255

Group type: EXPERIMENTAL
Intervention: Fludarabine-based regimen with rituximab
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fludarabine-based regimen without rituximab
Number of subjects: 42
Study: 32612522

Group type: EXPERIMENTAL
Intervention: SMR/Theta Neurofeedback Training
Number of subjects: 0
Study: 32612576

Group type: EXPERIMENTAL
Intervention: Urinary exosomal thyroglobulin measurement
Number of subjects: 0
Study: 32612737

Group type: EXPERIMENTAL
Intervention: Nasal provocation test with house dust mite (HDM)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Total IgE and house dust mite specific IgE
Number of subjects: 131

Group type: COMPARATOR
Intervention: Nasal IgE to HDM allergens
Number of subjects: 131
Study: 32612738

Group type: EXPERIMENTAL
Intervention: Skin prick testing with a panel of 12 allergens
Number of subjects: 1671

Group type: EXPERIMENTAL
Intervention: Skin prick testing
Number of subjects: 1671
Study: 32613082

Group type: EXPERIMENTAL
Intervention: dlPFC stimulation by iTBS alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: dlPFC stimulation by iTBS while simultaneously performing a cognitive task
Number of subjects: 40

Group type: COMPARATOR
Intervention: vertex (control) iTBS stimulation
Number of subjects: 40
Study: 32613089

Group type: EXPERIMENTAL
Intervention: Low-dose lung irradiation (LD-RT) combined with pharmacological treatment
Number of subjects: 106

Group type: COMPARATOR
Intervention: Pharmacological treatment only
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Low-dose lung irradiation (LD-RT)
Number of subjects: 106
Study: 32613319

Group type: EXPERIMENTAL
Intervention: Turner syndrome (TS) group
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (without TS)
Number of subjects: 168
Study: 32613402

Group type: EXPERIMENTAL
Intervention: Experimental formula with high beta-PA (20-25%) from cow's milk fat and 0.5 g GOS/100 ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard infant formula with low beta-PA (< 10%) without prebiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast-fed reference group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 32614159

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 54
Study: 32614327

Group type: EXPERIMENTAL
Intervention: Triaxial accelerometer sensor placed on the anterior chest to monitor body positions 24-hours daily through a 4-week monitoring period.
Number of subjects: 2
Study: 32614379

Group type: EXPERIMENTAL
Intervention: Maternal iron absorption accounting for iron transferred to the fetus
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Maternal iron absorption accounting for iron retained within the placenta
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Net transfer of iron to the neonate
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Neonatal hepcidin
Number of subjects: 68
Study: 32614391

Group type: EXPERIMENTAL
Intervention: Estrone (E1)
Number of subjects: 5325

Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Number of subjects: 5325

Group type: COMPARATOR
Intervention: Undetectable E2 vs detectable E2
Number of subjects: 5325

Group type: EXPERIMENTAL
Intervention: Linear regression model including age, BMI, E1, and testosterone
Number of subjects: 5325
Study: 32614451

Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Tests (RDTs) for HCV detection in HIV-uninfected samples (n=384)
Number of subjects: 1710

Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Tests (RDTs) for HCV detection in HIV-infected samples (n=264)
Number of subjects: 1710
Study: 32614698

Group type: EXPERIMENTAL
Intervention: Pyrotinib monotherapy
Number of subjects: 60
Study: 32614702

Group type: EXPERIMENTAL
Intervention: Docetaxel-based chemotherapy
Number of subjects: 2887

Group type: COMPARATOR
Intervention: Non-docetaxel-based chemotherapy
Number of subjects: 2887
Study: 32614835

Group type: EXPERIMENTAL
Intervention: FLAIR post-contrast MRI
Number of subjects: 25

Group type: COMPARATOR
Intervention: T1 weighted imaging (T1WI) post-contrast MRI
Number of subjects: 25
Study: 32614963

Group type: EXPERIMENTAL
Intervention: Treatment-free remission (TFR) after stopping tyrosine kinase inhibitors (TKIs)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Patients with fluctuating minimal residual disease (MRD)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Patients with stable MRD
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Late molecular recurrences (LMRec) after 2 years in TFR
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: MRec after 2 years in TFR
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Overall MRec
Number of subjects: 128
Study: 32615102

Group type: EXPERIMENTAL
Intervention: Proton beam radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photon beam radiotherapy
Number of subjects: 0
Study: 32615108

Group type: EXPERIMENTAL
Intervention: Avapritinib (300 mg recommended phase 2 dose, administered orally once daily)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Avapritinib (varied doses from 30 mg to 600 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Avapritinib (600 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose of Avapritinib
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Recommended phase 2 dose of Avapritinib
Number of subjects: 82
Study: 32615192

Group type: EXPERIMENTAL
Intervention: Incremental treadmill cardiopulmonary exercise test
Number of subjects: 35
Study: 32615331

Group type: EXPERIMENTAL
Intervention: Nerindocianine sodium (0.06 mg/kg, 0.12 mg/kg, 0.045 mg/kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nerindocianine sodium (0.06 mg/kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nerindocianine sodium
Number of subjects: 41
Study: 32615649

Group type: EXPERIMENTAL
Intervention: Diabetic patients on insulin
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Diabetic patients not on insulin
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Non-diabetic patients
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Non-diabetic patients with pre-operative HbA1c < 42 mmol/mol and random plasma glucose < 7.8 mmol/l
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 209
Study: 32615968

Group type: EXPERIMENTAL
Intervention: Modified method for neuraxial anesthesia
Number of subjects: 518

Group type: COMPARATOR
Intervention: Conventional method for neuraxial anesthesia
Number of subjects: 518
Study: 32616009

Group type: EXPERIMENTAL
Intervention: Wheat Soy Blend (WSB)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Lipid-based Nutrient Supplement (LNS)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: General food supplementation program
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Community Health Workers (CHWs) interaction
Number of subjects: 800
Study: 32616154

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32616162

Group type: EXPERIMENTAL
Intervention: Citizen responders arriving before EMS
Number of subjects: 438

Group type: COMPARATOR
Intervention: OHCAs where EMS arrived first
Number of subjects: 438